Drug
Pm8002
Pm8002: highest development phase Phase 3, developed by BioNTech. 4 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- BioNTech
Trials
| Drug | Phase | Indication |
|---|---|---|
| PM8002 NCT06419621 | Phase 3 | Triple Negative Breast Cancer(TNBC) |
| PM8002 NCT05756972 | Phase 2 | NSCLC |
| PM8002 NCT05864105 | Phase 2 | Hepatocellular Carcinoma |
| PM8002 NCT05879068 | Phase 2 | SCLC |
Latest
No recent events.
Follow Pm8002 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.